Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers

Background The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female BRCA1/BRCA2 mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated. Methods Israeli female cancer-free BRCA1/BR...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2021, Vol.185 (2), p.391-399
Main Authors: Galmor, Lee, Bernstein-Molho, Rinat, Sklair-Levy, Miri, Madoursky-Feldman, Dana, Zippel, Dov, Laitman, Yael, Friedman, Eitan
Format: Article
Language:English
Subjects:
Biopsy
BRCA1 protein
BRCA2 protein
Breast cancer
Cancer
Cancer research
Clinical Trial
Gene mutations
Genetic aspects
Genotyping
Mastectomy
Medical centers
Medicine
Medicine & Public Health
Mutation
Oncology
Oncology, Experimental
Prevention
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female BRCA1/BRCA2 mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated. Methods Israeli female cancer-free BRCA1/BRCA2 mutation carriers, who were followed at the high-risk clinic at Sheba Medical Center between January 2011 and April 2020 were eligible. Univariate Cox regression and log-rank test were used to study the crude association between potential predictors and performance of RRBM. Results Overall, 427 cancer-free BRCA1 ( n  = 218) or BRCA2 ( n  = 209) mutation carriers were included. Median age at genotyping was 33.6 years (interquartile range 26.8–41.8 years), median follow-up 4.4 years (range 0.1–7.6 years). Overall, 41/427 (9.6%) participants underwent RRBM, all of them within 5 years of genotyping. Being married (HR-2.57, p  = 0.017) and having a first degree relative with breast cancer (BC) (HR-2.19, p  = 0.017) were positively associated with RRBM, whereas any previous benign breast biopsy was negatively associated (HR-0.48, p  = 0.029) with performing RRBM. Conclusions RRBM is still infrequently elected by Israeli BRCA1/BRCA2 mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-020-05949-z